Safety and Effectiveness of Biphasic Insulin Aspart 30/70 (NovoMix®30) When Switching From Human Premix Insulin in Patients With Type 2 Diabetes: Subgroup Analysis From the 6-Month IMPROVE™ Observational Study

International Journal of Clinical Practice - United States
doi 10.1111/j.1742-1241.2009.02012.x
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Wiley

Related search

15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Drugs in R and D
Pharmacology
2018English

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Turkish Journal of Endocrinology and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients With Type 2 Diabetes: Results From the Jordanian Subgroup of the A<sub>1</Sub>chieve Study

Journal of Diabetes Mellitus
2014English

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2012English

Continuous Glucose Monitoring Guided Assessment of Concentrated 200 IU/Ml rDNA Human Premix 30/70 Insulin in Type 2 Diabetes Mellitus Patients

International Journal of Diabetes and Clinical Research
2019English

Switching From Glargine+insulin Aspart to Glargine+insulin Aspart 30 Before Breakfast Combined With Exercise After Dinner and Dividing Meals for the Treatment of Type 2 Diabetes Patients With Poor Glucose Control – A Prospective Cohort Study

BMC Endocrine Disorders
MedicineEndocrinologyMetabolismDiabetes
2018English

Efficacy and Safety of Three-Times-Daily Versus Twice-Daily Biphasic Insulin Aspart 30 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Combined With Oral Antidiabetic Drugs

Diabetes Research and Clinical Practice
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2019English

Safety, Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People With Diabetes Also Using Insulin Glargine: 12-Month Results From the GEMELLI 1 Trial

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy